Comparative effects of single-dose ceftriaxone versus three oral antibiotic regimens on stool colonization by resistant bacilli in children

Pediatric Infectious Disease Journal

Volumn 26, Issue 1, 2007, Pages 25-30

  Toltzis, Philip ^a   Dul, Michael ^a   O'Riordan, Mary Ann ^a   Toltzis, Hasida ^a   Blumer, Jeffrey L ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Acute otitis media; Antibiotic resistance; Ceftriaxone; Gram negative bacilli; Outpatient antibiotic therapy

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CEFPROZIL; CEFTRIAXONE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ACUTE OTITIS MEDIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; CHILD; CITROBACTER; CONTROLLED STUDY; ENTEROBACTER; ESCHERICHIA COLI; FECES ANALYSIS; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS; RANDOMIZATION; SCREENING; SINGLE DRUG DOSE;

ACUTE DISEASE; ADMINISTRATION, ORAL; AMOXICILLIN; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CEFTRIAXONE; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; FECES; FEMALE; GRAM-NEGATIVE BACTERIA; HUMANS; INFANT; INJECTIONS, INTRAMUSCULAR; MALE; OTITIS MEDIA;

EID: 33845979881     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000247130.11902.64     Document Type: Article

References (52)

1. Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries: French and Portuguese ICU Study Groups. JAMA. 1999;281:67-71.
2. Flournoy DJ, Reinert RL, Bell-Dixon C, Gentry CA. Increasing antimicrobial resistance in gram-negative bacilli isolated from patients in intensive care units. Am J Infect Control. 2000;28:244-250.
3. Toltzis P, Yamashita T, Vilt L, Blumer JL. Colonization with antibiotic-resistant gram-negative organisms in a pediatric intensive care unit. Crit Care Med. 1997;25:538-544.
4. National Nosocomial Infection Surveillance System. National Nosocomial Infections Surveillance (NNIS) System report: data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470-485.
5. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003;289:885-888.
6. Friedland I, Stinson L, Ikaiddi M, Harm S, Woods GL. Resistance in Enterobacteriaceae: results of a multicenter surveillance study, 1995-2000. Infect Control Hosp Epidemiol. 2003;24:607-612.
7. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991;115:585-590.
8. Jacobson KL, Cohen SH, Inciardi JF, et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms. Clin Infect Dis. 1995;21:1107-1113.
9. Gerding DN, Larson TA, Hughes RA, Weiler M, Shanholtzer C, Peterson LR. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother. 1991;35:1284-1290.
10. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999;43:1379-1382.
11. Kaye KS, Harris AD, Gold H, Carmeli Y. Risk factors for recovery of ampicillin-sulbactam-resistant Escherichia coli in hospitalized patients. Antimicrob Agents Chemother. 2000;44:1004-1009.
12. Fleisher GR, Rosenberg N, Vinci R, et al. Intramuscular versus oral antibiotic therapy for the prevention of meningitis and other bacterial sequelae in young, febrile children at risk for occult bacteremia. J Pediatr. 1994;124:504-512.
13. Klein JO. Management of the febrile child without a focus of infection in the era of universal pneumococcal immunization. Pediatr Infect Dis J. 2002;21:584-588.
14. American Academy of Pediatrics Subcommittee on the Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics. 2004;113:1451-1465.
15. Cohen R, Navel M, Grunberg J, et al. One dose ceftriaxone vs. ten days of amoxicillin/clavulanate therapy for acute otitis media: clinical efficacy and change in nasopharyngeal flora. Pediatr Infect Dis J. 1999;18:403-409.
16. Rice LB, Eckstein EC, DeVente J, Shlaes DM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis. 1996;23:118-124.
17. Medeiros AA. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin Infect Dis. 1997;24(suppl 1):S19-S45.
18. Kaye KS, Cosgrove S, Harris A, Eliopoulos GM, Carmeli Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother. 2001;45:2628-2630.
19. Nilsson-Ehle I, Nord CE, Ursing B. Ceftriaxone: pharmacokinetics and effect on the intestinal microflora in patients with acute bacterial infections. Scand J Infect Dis. 1985;17:77-82.
20. de Vries-Hospers HG, Tonk RH, van der Waaij D. Effect of intramuscular ceftriaxone on aerobic oral and faecal flora of 11 healthy volunteers. Scand J Infect Dis. 1991;23:625-633.
21. Arvidsson A, Leijd B, Nord CE, Angelin B. Interindividual variability in biliary excretion of ceftriaxone: effects on biliary lipid metabolism and on intestinal microflora. Eur J Clin Invest. 1988;18:261-266.
22. Bodey GP, Fainstein V, Garcia I, Rosenbaum B, Wong Y. Effect of broad-spectrum cephalosporins on the microbial flora of recipients. J Infect Dis. 1983;148:892-897.
23. Toltzis P, Dul M, O'Riordan MA, Toltzis H, Blumer JL. Impact of amoxicillin on pneumococcal colonization compared with other therapies for acute otitis media. Pediatr Infect Dis J. 2005;24:24-28.
24. Toltzis P, Dul MJ, Hoyen C, et al. The effect of antibiotic rotation on colonization with antibiotic-resistant bacilli in a neonatal intensive care unit. Pediatrics. 2002;110:707-711.
25. Khattree K, Naik DN. Applied Multivariate Statistics with SAS Software. Cary, NC: SAS Institute; 1999.
26. Fung-Tomc JC, Gradelski E, Huczko E, Dougherty TJ, Kessler RE, Bonner DP. Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins. Antimicrob Agents Chemother. 1996;40:1289-1293.
27. Muller A, Lopez-Lozano JM, Bertrand X, Talon D. Relationship between ceftriaxone use and resistance to third-generation cephalosporins among clinical strains of Enterobacter cloacae. J Antimicrob Chemother. 2004;54:173-177.
28. Michea-Hamzehpour M, Auckenthaler R, Kunz J, Pechere JC. Effect of a single dose of cefotaxime or ceftriaxone on human faecal flora: a double-blind study. Drugs. 1988;35(suppl 2):6-11.
29. Welling GW, Meijer-Severs GJ, Helmus G, et al. The effect of ceftriaxone on the anaerobic bacterial flora and the bacterial enzymatic activity in the intestinal tract. Infection. 1991;19:313-316.
30. Brautigam HH, Knothe H, Rangoonwala R. Impact of cefotaxime and ceftriaxone on the bowel and vaginal flora after single-dose prophylaxis in vaginal hysterectomy. Drugs. 1988;35(suppl 2):163-168.
31. Guggenbichler JP, Kofler J. Influence of third-generation cephalosporins on aerobic intestinal flora. J Antimicrob Chemother. 1984;14(suppl B):67-70.
32. Black F, Einarsson K, Lidbeck A, Orrhage K, Nord CE. Effect of lactic acid producing bacteria on the human intestinal microflora during ampicillin treatment. Scand J Infect Dis. 1991;23:247-254.
33. Nord CE, Movin G, Stalberg D. Impact of cefixime on the normal intestinal microflora. Scand J Infect Dis. 1988;20:547-552.
34. Edlund C, Stark C, Nord CE. The relationship between an increase in beta-lactamase activity after oral administration of three new cephalosporins and protection against intestinal ecological disturbances. J Antimicrob Chemother. 1994;34:127-138.
35. Lode H, Von der Hoh N, Ziege S, Borner K, Nord CE. Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. Scand J Infect Dis. 2001;33:899-903.
36. Edlund C, Alvan G, Barkholt L, Vacheron F, Nord CE. Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora. J Antimicrob Chemother. 2000;46:741-749.
37. Adachi JA, Ericsson CD, Jiang ZD, et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis. 2003;37:1165-1171.
38. Gordillo ME, Singh KV, Murray BE. In vitro activity of azithromycin against bacterial enteric pathogens. Antimicrob Agents Chemother. 1993;37:1203-1205.
39. Khan WA, Seas C, Dhar U, Salam MA, Bennish ML. Treatment of shigellosis, V: comparison of azithromycin and ciprofloxacin; a double-blind, randomized, controlled trial. Ann Intern Med. 1997;126:697-703.
40. Andremont A, Sancho-Garnier H, Tancrede C. Epidemiology of intestinal colonization by members of the family Enterobacteriaceae highly resistant to erythromycin in a hematology-oncology unit. Antimicrob Agents Chemother. 1986;29:1104-1107.
41. Heimdahl A, Nord CE. Influence of erythromycin on the normal human flora and colonization of the oral cavity, throat and colon. Scand J Infect Dis. 1982;14:49-56.
42. Kim YK, Pai H, Lee HJ, et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother. 2002;46:1481-1491.
43. Zaoutis TE, Goyal M, Chu JH, et al. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics. 2005;115:942-949.
44. Wong-Beringer A, Hindler J, Loeloff M, et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis. 2002;34:135-146.
45. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol. 2001;39:2206-2212.
46. Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y. High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2005;49:2137-2139.
47. Nord CE, Grahnen A, Eckernas SA. Effect of loracarbef on the normal oropharyngeal and intestinal microflora. Scand J Infect Dis. 1991;23:255-260.
48. Mulligan ME, Citron D, Gabay E, Kirby BD, George WL, Finegold SM. Alterations in human fecal flora, including ingrowth of Clostridium difficile, related to cefoxitin therapy. Antimicrob Agents Chemother. 1984;26:343-346.
49. Beyer G, Hiemer-Bau M, Ziege S, Edlund C, Lode H, Nord CE. Impact of moxifloxacin versus clarithromycin on normal oropharyngeal microflora. Eur J Clin Microbiol Infect Dis. 2000;19:548-550.
50. Brismar B, Edlund C, Nord CE. Impact of cefpodoxime proxetil and amoxicillin on the normal oral and intestinal microflora. Eur J Clin Microbiol Infect Dis. 1993;12:714-719.
51. Matute AJ, Schurink CA, Krijnen RM, Florijn A, Rozenberg-Arska M, Hoepelman IM. Double-blind, placebo-controlled study comparing the effect of azithromycin with clarithromycin on oropharyngeal and bowel microflora in volunteers. Eur J Clin Microbiol Infect Dis. 2002;21:427-431.
52. Lode H, Muller C, Borner K, Nord CE, Koeppe P. Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers. Antimicrob Agents Chemother. 1992;36:144-149.